April 30, 2013 13:45 ET

Overall U.S. Costs of Cancer to Spike to $158 Billion by 2020

NEW YORK, NY--(Marketwired - Apr 30, 2013) - TriMark Publications (, a global leader in biotechnology, healthcare and life sciences publishing, announces the release of its Cancer Diagnostic Testing report. Cancer diagnostic testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The American Cancer Society estimates that approximately 1,660,290 new cancer cases are expected to be diagnosed in 2013. Overall costs of the disease will reach at least $158 billion in the U.S. by 2020.

The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories.

The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the cancer diagnostic testing market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary on the company's market position. The following areas are addressed in this analysis:

  • DNA Markers
  • Serum Proteins
  • Enzymes
  • Occult Blood
  • Histology and In Situ Hybridization (ISH)
  • Cervical Cytology
  • Immunohistochemistry
  • In Vivo Detection Cancer Products
  • Radionuclides and X-Ray Detection Products
  • Human Papillomavirus (HPV) Testing
  • Bladder Cancer Testing
  • Tumor Assays for Adjuvant Chemotherapy
  • Organ Specific Tumor Markers
  • Colon Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Lung Cancer
  • Testicular Cancer
  • Bladder Cancer
  • Hepatic Cancer
  • Stomach Cancer
  • Malignant Melanoma
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastoid Leukemia (ALL)
  • Lymphoma

For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information